Research across Glaucoma
Related studies from across the Glaucoma family.
172 trials tracked for Open-angle glaucoma: 79 in phase 3 or 4 and 17 with published results. The most-cited published study has 216 citations.
Showing the 50 most-cited and recently-updated of 172 trials. Browse the full registry →
Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.
Pharmacological management for open-angle glaucoma includes several classes of agents. Beta-blocker monotherapy demonstrated a significant reduction in mean intraocular pressure (IOP) at 8 AM compared to baseline (-25.36% vs -4.71%, p<0.0001) 5. Prostaglandin analogs such as travoprost showed high rates of patients reaching target IOP goals (≤18 mmHg) in both standard and BAK-free formulations [16, 21, 22].
Combination therapies involving Brinzolamide and brimonidine or briminidine consistently demonstrated significant reductions in mean diurnal IOP at week 6 compared to baseline (-24.7% and -22.27% respectively) [11, 13, 14]. Additionally, the Brinzolamide/timolol fixed combination was evaluated for its ability to reach target IOP goals 19.
Other established interventions include Netarsudil ophthalmic solution 4, Mitomycin-C injection 8, and various prostaglandin analogs like Bimatoprost [18, 20] and Monoprost 9.
AI synthesis of 7 cited trials, updated Jun 22, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.
Related studies from across the Glaucoma family.